title: Emerging molecules in the interface between skeletal system and innate immunity.
abstract: Despite the improved treatment of bone destruction, significant unmet medical need remains. For example, there is a limited benefit of continued bisphosphonate therapy for osteoporotic patients, and only minor populations of rheumatoid arthritis patients obtain biologic-free remission. Therefore, the identification of a novel therapeutic target for bone destructive diseases remains an important issue in the field of skeletal biology. To date there has been little progress in identifying osteo-innate-immunological regulators that could be used for the prophylactic treatment of inflammatory bone destruction. Recently, we identified several new molecules that are critical osteo-innate-immunological regulators by using gene targeting technology. These findings may offer an invaluable opportunity to regulate bone-destructive diseases, such as osteoporosis and rheumatoid arthritis.
authors.affiliation: Laboratory of Host Defense, Osaka University, Osaka 565-0871, Japan; WPI Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, Japan. Electronic address: maruyama@biken.osaka-u.ac.jp.
authors.forename: Kenta
authors.initials: K
authors.lastname: Maruyama
authors.affiliation: Laboratory of Host Defense, Osaka University, Osaka 565-0871, Japan; WPI Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, Japan; Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan. Electronic address: sakira@biken.osaka-u.ac.jp.
authors.forename: Shizuo
authors.initials: S
authors.lastname: Akira
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001842:Bone and Bones / Q000187:drug effects*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D010024:Osteoporosis / Q000188:drug therapy
keywords: Bone destruction; Innate immunity; Macrophage; Neutrophil; Osteoblast; Osteoclast